An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) concurrent with Cisplatin and Radiotherapy in histologically Documented Squamous Cell Carcinoma of the Cervix.

Trial Profile

An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) concurrent with Cisplatin and Radiotherapy in histologically Documented Squamous Cell Carcinoma of the Cervix.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Cisplatin; Nimotuzumab
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top